Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.17
+2.6%
$1.15
$0.98
$1.89
$36.58M-0.6863,689 shs15,173 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$18.20
-1.4%
$17.66
$14.51
$22.99
$63.88M0.67,892 shs6,218 shs
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$0.02
$0.02
$0.00
$0.03
$21.35M0.99309,155 shs23,850 shs
Beyond Air, Inc. stock logo
XAIR
Beyond Air
$1.18
+0.4%
$1.63
$1.13
$6.36
$42.53M-0.18307,327 shs92,518 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-1.72%+2.24%-9.52%-15.56%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-0.22%-1.70%+7.20%-14.22%+15.52%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
-18.61%-21.67%-8.68%-18.61%-25.42%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-8.20%-1.26%-30.47%-17.83%-78.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
3.7609 of 5 stars
3.04.00.04.42.40.00.6
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/AN/AN/AN/A
Beyond Air, Inc. stock logo
XAIR
Beyond Air
3.6286 of 5 stars
3.52.00.03.51.10.81.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50113.64% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/A
Beyond Air, Inc. stock logo
XAIR
Beyond Air
3.00
Buy$11.25853.39% Upside

Current Analyst Ratings

Latest CODX, SNWV, XAIR, and PDEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.37N/AN/A$2.81 per share0.42
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$46.09M1.39$2.20 per share8.26$8.91 per share2.04
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$20.40M1.05N/AN/A($0.04) per share-0.47
Beyond Air, Inc. stock logo
XAIR
Beyond Air
N/AN/AN/AN/A$1.40 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Confirmed)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$7.07M$0.7524.27N/A5.59%8.97%5.40%5/2/2024 (Estimated)
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
-$25.81M-$0.03N/AN/A-126.52%N/A-32.63%5/10/2024 (Estimated)
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$55.82M-$2.13N/AN/AN/AN/A-199.90%-106.00%6/27/2024 (Estimated)

Latest CODX, SNWV, XAIR, and PDEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$0.21N/A+$0.21N/AN/AN/A  
3/21/2024Q4 2023
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A$0.03+$0.03$0.03N/A$6.99 million
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
2/12/202412/31/2023
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$0.61-$0.50+$0.11-$0.50$0.49 million$0.39 million    
2/8/2024Q2 2024
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/A$0.14+$0.14$0.14N/A$12.59 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/A
Beyond Air, Inc. stock logo
XAIR
Beyond Air
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.26
3.66
2.16
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A
0.15
0.11
Beyond Air, Inc. stock logo
XAIR
Beyond Air
0.61
3.39
3.26

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
42.53%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
31.50%

Insider Ownership

CompanyInsider Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
42.60%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
16.40%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
19.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1453.51 million2.02 millionNot Optionable
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
311.14 billion953.51 millionNot Optionable
Beyond Air, Inc. stock logo
XAIR
Beyond Air
9836.04 million29.19 millionOptionable

CODX, SNWV, XAIR, and PDEX Headlines

SourceHeadline
Beyond Paradises dating storyline is a breath of fresh airBeyond Paradise's dating storyline is a breath of fresh air
digitalspy.com - April 12 at 6:47 PM
Beyond the Horizon Air and Space Show ends with record number of spectatorsBeyond the Horizon Air and Space Show ends with record number of spectators
msn.com - April 10 at 1:56 PM
Beyond the Horizon Air Show attracts thousands to Maxwell AFBBeyond the Horizon Air Show attracts thousands to Maxwell AFB
wsfa.com - April 7 at 2:22 PM
Beyond Air (NASDAQ:XAIR) Trading 3.2% Higher Beyond Air (NASDAQ:XAIR) Trading 3.2% Higher
marketbeat.com - April 5 at 12:43 AM
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com - March 21 at 1:01 PM
Beyond Air Prices Direct Offering Of $16 Mln Of Shares, WarrantsBeyond Air Prices Direct Offering Of $16 Mln Of Shares, Warrants
markets.businessinsider.com - March 20 at 6:51 PM
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and WarrantsBeyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
globenewswire.com - March 20 at 9:00 AM
"There is a great need to look for mobility alternatives and we are going to operate with electric vehicles in the air""There is a great need to look for mobility alternatives and we are going to operate with electric vehicles in the air"
lapoliticaonline.com - March 18 at 11:59 PM
Beyond Paradise star teases a different side to her character in season 2Beyond Paradise star teases a different side to her character in season 2
yahoo.com - March 16 at 11:37 PM
Will Renewed Nvidia Excitement Lift the Entire Market?Will Renewed Nvidia Excitement Lift the Entire Market?
realmoney.thestreet.com - February 23 at 10:34 AM
Bed Bath & Beyond has a new CEO, air quality’s rising impact on real estate and moreBed Bath & Beyond has a new CEO, air quality’s rising impact on real estate and more
yahoo.com - February 20 at 5:50 PM
Beyond Air (XAIR) Earnings Dates & ReportsBeyond Air (XAIR) Earnings Dates & Reports
investing.com - February 13 at 10:29 PM
Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call TranscriptBeyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript
msn.com - February 13 at 12:27 PM
Recap: Beyond Air Q3 EarningsRecap: Beyond Air Q3 Earnings
benzinga.com - February 12 at 9:23 PM
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue EstimatesBeyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
msn.com - February 12 at 9:23 PM
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
finance.yahoo.com - February 12 at 4:22 PM
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
finance.yahoo.com - February 12 at 4:22 PM
A Preview Of Beyond Airs EarningsA Preview Of Beyond Air's Earnings
benzinga.com - February 9 at 2:21 PM
AI model gives air quality forecasts that are similar to weather forecastsAI model gives air quality forecasts that are similar to weather forecasts
msn.com - February 3 at 10:01 PM
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and WebcastBeyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
finance.yahoo.com - January 18 at 1:43 PM
Beyond Air Inc (XAIR) may enjoy gains as insiders got busy in the recent daysBeyond Air Inc (XAIR) may enjoy gains as insiders got busy in the recent days
knoxdaily.com - January 2 at 12:58 PM
Medical Device Player Beyond Airs Subsidiary Reveals Encouraging Data From Early-Stage Cancer StudyMedical Device Player Beyond Air's Subsidiary Reveals Encouraging Data From Early-Stage Cancer Study
msn.com - December 27 at 12:25 PM
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid TumorsBeyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
finance.yahoo.com - December 27 at 12:25 PM
Beyond Air Independent Director Acquires 102% More StockBeyond Air Independent Director Acquires 102% More Stock
finance.yahoo.com - December 23 at 9:57 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Pro-Dex logo

Pro-Dex

NASDAQ:PDEX
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
SANUWAVE Health logo

SANUWAVE Health

OTCMKTS:SNWV
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide therapeutic treatment of musculoskeletal conditions. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
Beyond Air logo

Beyond Air

NASDAQ:XAIR
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.